No Data
Cartesian Therapeutics(RNAC.US) 10% Shareholder Buys US$7.37 Million in Common Stock
$Cartesian Therapeutics(RNAC.US)$ 10% Shareholder SPRINGER TIMOTHY A purchased 431.94K shares of common stock on Nov 14, 15, 18, 2024 at an average price of $17.0707 for a total value of $7.37
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Cuts Target Price to $41
Cartesian Therapeutics Price Target Cut to $41.00/Share From $45.00 by HC Wainwright & Co.
Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oppenheimer Maintains Cartesian Therapeutics(RNAC.US) With Hold Rating
No Data
No Data